Business Wire

CMOs Face a ‘Reputation and Results’ Reckoning, According to NIQ’s 2026 Outlook

19.11.2025 12:00:00 CET | Business Wire | Press Release

Share

NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today released its CMO Outlook: Guide to 2026 report, revealing how chief marketing officers (CMOs) are navigating a critical inflection point between brand building and revenue accountability. According to the report, 83% of CMOs remain confident in their brand’s equity, even as they face tightening budgets and heightened scrutiny over ROI.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118947080/en/

NIQ CMO Outlook: Guide to 2026

“Every marketing dollar is now under the microscope,” said Marta Cyhan-Bowles, Chief Communications Officer & Head of Global Marketing COE, NIQ. “With organizations prioritizing cost reductions, CMOs are being challenged not just to spend wisely, but to prove how marketing directly drives awareness, growth, and loyalty. It’s no longer just about efficiency; it’s about proving impact – all with largely flat budgets.”

Key Findings from NIQ’s 2026 CMO Outlook

CMOs remain confident in brand equity but are shifting focus under pressure.

  • 83% of CMOs still view their brand as a key commercial asset, yet only 55% allocate 60% or more of their budgets to long-term brand building, down from 59% of CMO respondents last year.
  • Confidence in brand purpose has fallen from 83% to 71%.
  • Despite strong belief in brand equity, 84% of CMOs now prioritize ROI as their primary metric for budget allocation, signaling pressure to drive short term conversion over long-term brand growth.
  • Only 69% of CMOs say their CEO and chief financial officer (CFO) support long-term brand investment, a sharp decline from 80% last year. These shifts underscore a growing tension between brand stewardship and financial scrutiny.

Data fragmentation threatens ROI clarity.

  • 54% of CMOs say connecting data from different sources is a major barrier to insight generation.
  • One-third rely on 5 to 15 tools to measure ROI; in some cases, more than 15.
  • Only 37% report having a centralized data repository accessible to all stakeholders.

AI integration accelerates, but CMOs are now measured by impact, not access.

  • Generative AI tools are widely used for content generation (69%), personalization (64%), and media planning and optimization (55%).
  • The focus has shifted from experimentation to proving measurable business outcomes, with CMOs expected to quantify AI’s ROI at the executive level.

Retail media networks (RMNs) surge as the next frontier of marketing ROI.

  • 69% of CMOs recognize RMNs as increasingly critical, and 67% plan to increase investment in the next year.
  • While RMNs offer conversion-rich environments and unprecedented targeting precision, they also increase media fragmentation, intensifying pressure on CMOs to integrate cross-channel data through AI-driven advanced modeling and analytics.
  • Ongoing integration of off-platform campaigns with on-platform RMN ads remains essential for a cohesive full funnel strategy and stronger conversion.
  • Many CMOs now view digital partnerships with retailers as long-term investments that accelerate SKU growth and strengthen distribution.

“Marketers are redefining what performance means,” Cyhan-Bowles said. “Data, AI, and retail media networks are reshaping the marketing playbook, and the most successful CMOs will be those who connect these forces to demonstrate measurable value for the organization.”

Strategic Focus Areas/Next Steps

As CMOs look ahead to 2026, NIQ’s findings point to four priorities that will define high-performing marketing organizations.

  • Data integration and connectivity: Building unified, centralized data systems to create a single source of truth for marketing performance and enable faster, insight-driven decisions.
  • AI implementation and ROI measurement: Maximizing existing AI capabilities, investing in new AI solutions that drive measurable efficiencies, and clearly articulating martech’s business impact to executive stakeholders.
  • Omnichannel strategy and retail media integration: Modernizing the media mix by balancing digital acceleration with traditional channels, leveraging RMN efficiencies to offset lower-converting high value channels, while maintaining full-funnel coverage across the consumer journey.
  • Talent and capability investment: Upskilling marketing teams to leverage analytics and AI tools effectively, enabling agile decision-making and sustained brand growth even amid economic pressure.

Together, these focus areas position CMOs to move beyond efficiency toward long-term resilience, driving both long-term brand equity and measurable business results.

The integration of AI and data driven strategies is not only a response to budget constraints but also a proactive approach to sustainable growth in a challenging economic environment.

Download the report for detailed insights and guidance for CMOs.

Note to Editors:

NIQ executives, including Chief Communications Officer & Head of Global Marketing COE Marta Cyhan-Bowles, will speak about findings from the 2026 CMO Outlook at The Wall Street Journal’s CMO Council Summit on November 19, 2025, in a session titled “From Data to Decisions: The CMO’s ROI Reckoning.”

The 2026 CMO Outlook underscores NIQ’s commitment to delivering actionable intelligence to help brands navigate a fast-evolving media and technology landscape. By integrating advanced analytics with The Full View™ of consumer behavior, NIQ equips marketing leaders to measure what matters and act with confidence.

About the report:

NIQ’s CMO Outlook: Guide to 2026 report is based on a survey of more than 250 CMOs and senior marketing decision-makers from leading companies across industries and regions. The survey covers 14 countries representing Asia Pacific, Europe, Latin America, and North America. Marketing leaders are defined as CMOs or Brand Heads, Directors or VPs of Marketing, Brand, Marketing Operations, or Customer Experience.

About NIQ:

NielsenIQ (NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. Our global reach spans over 90 countries covering approximately 85% of the world’s population and more than $7.2 trillion in global consumer spend. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™.

For more information, please visit niq.com.

Forward-Looking Statements Disclaimer

This CMO Outlook: Guide to 2026 press release may contain forward-looking statements regarding anticipated consumer behaviors, market trends, and industry developments. These statements reflect current expectations and projections based on available data, historical patterns, and various assumptions. Words such as “expects,” “anticipates,” “projects,” “believes,” “forecasts,” “plan,” “look ahead,” and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future outcomes and are subject to inherent uncertainties, including changes in consumer preferences, economic conditions, technological advancements, and competitive dynamics. Actual results may differ materially from those expressed or implied in these statements. While we strive to base our insights on reliable data and sound methodologies, we undertake no obligation to update any forward-looking statements to reflect future events or circumstances, except to the extent required by applicable law.

© 2025 Nielsen Consumer LLC. All Rights Reserved.

NIQ-GENERAL

View source version on businesswire.com: https://www.businesswire.com/news/home/20251118947080/en/

Contacts

Media Contact: media.relations@niq.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye